Publicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (26)

2021

  1. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

  2. Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombopenia

    Medicina Clinica, Vol. 157, Núm. 4, pp. 191-198

  3. miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis

    Haematologica, Vol. 106, Núm. 6, pp. 1636-1646

2017

  1. Regulation of TFPIα expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens

    Scientific Reports, Vol. 7

2016

  1. Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect

    Journal of Thrombosis and Haemostasis, Vol. 14, Núm. 8, pp. 1549-1560

  2. Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria

    Medicina Clinica

2013

  1. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study

    Thrombosis Research, Vol. 132, Núm. 6, pp. 666-670

  2. Association of the thrombomodulin gene c.1418c7gt;t polymorphism with thrombomodulin levels and with venous thrombosis risk

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 33, Núm. 6, pp. 1435-1440

2012

  1. Diagnóstico, tratamiento y seguimiento de la trombocitopenia inmune primaria

    Medicina Clinica

  2. Effects of oral anticoagulant therapy and haplotype 1 of the endothelial protein C receptor gene on activated protein C levels

    Thrombosis and Haemostasis, Vol. 107, Núm. 3, pp. 448-457

  3. miR-133a regulates Vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the Vitamin K cycle

    Molecular Medicine, Vol. 18, Núm. 11, pp. 1466-1472

2010

  1. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm

    Nature Genetics, Vol. 42, Núm. 8, pp. 692-697

2009

  1. Antithrombin Cambridge ll (A384S) supports a role for antithrombin deficiency in arterial thrombosis

    Thrombosis and Haemostasis, Vol. 101, Núm. 3, pp. 483-486

2008

  1. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms

    Haematologica, Vol. 93, Núm. 5, pp. 729-734

  2. Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism

    Thrombosis Research, Vol. 122, Núm. 3, pp. 320-327

2004

  1. Homozygous deficiency of heparin cofactor II: Relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis

    Circulation, Vol. 110, Núm. 10, pp. 1303-1307

2002

  1. Prothrombin A19911G and G20210A polymorphisms' role in thrombosis

    British Journal of Haematology, Vol. 118, Núm. 2, pp. 610-614

1996

  1. Quantification of circulating activated protein C in human plasma by immunoassays - Enzyme levels are proportional to total protein C levels

    Thrombosis and Haemostasis, Vol. 75, Núm. 1, pp. 56-61

1995

  1. Activation of the protein C pathway in acute sepsis

    Thrombosis Research, Vol. 79, Núm. 1, pp. 83-93

1993

  1. Complex formation between protein c inhibitor and tissue plasminogen activator during thrombolytic therapy. Evidence of activation of protein C pathway

    Fibrinolysis and Proteolysis, Vol. 7, Núm. 5, pp. 308-315